Nothing Special   »   [go: up one dir, main page]
Skip to main content

Advertisement

Springer Nature Link
Log in

Raloxifene Inhibits NF-kB Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxictiy

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Cisplatin induced nephrotoxicity is the chief obstacle in the use of cisplatin as chemotherapeutic agent. However, it remains as most widely employed anticancer agent to treat various solid tumours like head-neck, testicular, ovarian and mammary gland cancer. Raloxifene is claimed to be potent anti-inflammatory as well as anti-cancer agent. The present study was carried out to explore the effect of pre-treatment of raloxifene on cisplatin induced nephrotoxicity and its anti-tumour activity in 7, 12 dimethyl benz [a] anthracene induced mammary tumour in animal model. Renal damage was accessed by measuring serum level of creatinine, blood urea nitrogen and albumin whereas systemic inflammation was accessed by measuring level of pro-inflammatory cytokines like tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10) and nuclear factor kappa B (NFκB). Moreover, assessment of tumour reduction was done by measuring tumour volume and percentage tumour reduction. A single dose of cisplatin (7.5 mg/kg) resulted in significant increase in serum creatinine, blood urea nitrogen, NF-kB, TNF-α and IL-6 levels along with decrease in albumin and IL-10 levels. However, there were no significant changes in raloxifene (8 mg/kg) treated group. Pre-treatment of raloxifene (8 mg/kg) caused marked decrease in serum creatinine, blood urea nitrogen, TNF-α and IL-6 levels whereas increase in albumin and IL-10 levels. However, pre-treatment of raloxifene showed maximum tumour reduction as compared to cisplatin and raloxifene treated groups. The present study demonstrates that raloxifene potentiates anti-tumour activity of cisplatin with simultaneous reduction in its nephrotoxicity, and this effect is attributed to its direct anti-inflammatory activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Bogdanovic G, Kojic V, Srdic T, Jakimov D, Djuran MI, Bugarcic ZD, Baltic M, Baltic VV (2002) Growth effects of some platinum(II) complexes with sulfur-containing carrier ligands on MCF7 human breast cancer cell line upon simultaneous administration with taxol. Met Based Drugs 9:33–43

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Aisner J, Jacobs M, Sinabaldi V, Gray W, Eisenberger M (1994) Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Semin Oncol 21:35–44

    CAS  PubMed  Google Scholar 

  3. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–584

    Article  CAS  PubMed  Google Scholar 

  4. Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173–1183

    Article  CAS  PubMed  Google Scholar 

  5. Ramesh G, Kimball SR, Jefferson LS, Reeves WB (2007) Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol 292:F812–F819

    Article  CAS  PubMed  Google Scholar 

  6. Basnakian AG, Apostolov EO, Yin X, Napirei M, Mannherz HG, Shah SV (2005) Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol 16:697–702

    Article  CAS  PubMed  Google Scholar 

  7. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464

    Article  CAS  PubMed  Google Scholar 

  8. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8–15

    Article  CAS  PubMed  Google Scholar 

  9. Ramesh G, Brian Reeves W (2006) Cisplatin increases TNF-alpha mRNA stability in kidney proximal tubule cells. Ren Fail 28:583–592

    Article  CAS  PubMed  Google Scholar 

  10. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124

    Article  PubMed  Google Scholar 

  11. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Ramesh G, Reeves WB (2003) TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610–F618

    Article  CAS  PubMed  Google Scholar 

  13. Ramesh G, Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumour necrosis factor-alpha. Kidney Int 65:490–499

    Article  CAS  PubMed  Google Scholar 

  14. Dong Z, Atherton SS (2007) Tumour necrosis factor-alpha in cisplatin nephrotoxicity: a homebred foe? Kidney Int 72:5–7

    Article  CAS  PubMed  Google Scholar 

  15. Kaya H, Ozkaya O, Sezik M, Arslanoglu E, Yilmaztepe A, Ulukaya E (2005) Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. Maturitas 50:182–188

    Article  CAS  PubMed  Google Scholar 

  16. Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhauser M (2012) Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Eur Spine J 21:2407–2417

    Article  PubMed Central  PubMed  Google Scholar 

  17. Shibata MA, Morimoto J, Shibata E, Kurose H, Akamatsu K, Li ZL, Kusakabe M, Ohmichi M, Otsuki Y (2010) Raloxifene inhibits tumour growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC Cancer 10:566

    Article  PubMed Central  PubMed  Google Scholar 

  18. Galien R, Garcia T (1997) Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 25:2424–2429

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V, Franchimont N (2006) Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 69:1615–1623

    Article  CAS  PubMed  Google Scholar 

  20. K.K. Thakur, N.B. Bolshette, C. Trandafir, V.S. Jamdade, A. Istrate, R. Gogoi, A. Cucuianu, Role of toll-like receptors in multiple myeloma and recent advances. Exp Hematol (2014) 43(3):158–167

    Article  PubMed  Google Scholar 

  21. Kumar P, Bolshette NB, Jamdade VS, Mundhe NA, Thakur KK, Saikia KK, Lahkar M (2013) Breast cancer status in India: an overview. J Carcinog 3:177–183

    Google Scholar 

  22. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G (2003) Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177:423–433

    Article  CAS  PubMed  Google Scholar 

  23. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60:2118–2128

    Article  CAS  PubMed  Google Scholar 

  24. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16:46–52

    Article  CAS  PubMed  Google Scholar 

  25. Kumar P, Kadakol A, Shasthrula P, Mundhe NA, Jamdade VS, Barua CC, Gaikwad AB (2015) Curcumin as an adjuvant to breast cancer treatment. Anti Cancer Agents Med Chem 15:647–656

    Article  CAS  Google Scholar 

  26. T. Whitsett, M. Carpinter, C.A. Lamartiniere (2006) Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5 15.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Stuhr LE, Iversen VV, Straume O, Maehle BO, Reed RK (2004) Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett 210(1):35–40

    Article  CAS  PubMed  Google Scholar 

  28. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M (2003) Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63:72–82

    Article  CAS  PubMed  Google Scholar 

  29. Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL (2012) Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor kappaB signaling. J Pharmacol Exp Ther 341:725–734

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490–2518

    Article  CAS  Google Scholar 

  31. Schrier RW (2002) Cancer therapy and renal injury. J Clin Invest 110:743–745

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The first author expresses his sincere thanks to National Institute of Pharmaceutical Education and Research (NIPER), Guwahati for providing financial assistance to carry out this work.

Author information

Authors and Affiliations

  1. Laboratory of Molecular Pharmacology and Toxicology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati, Assam, 781032, India

    Vinayak Sudhir Jamdade, Nitin A. Mundhe, Parveen Kumar, Venkatesh Tadla & Mangala Lahkar

  2. Laboratory of Pharmacology, Department of Pharmacology, Gauhati Medical College, Guwahati, Assam, 781032, India

    Mangala Lahkar

Authors
  1. Vinayak Sudhir Jamdade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nitin A. Mundhe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parveen Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Venkatesh Tadla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mangala Lahkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinayak Sudhir Jamdade.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests or conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jamdade, V.S., Mundhe, N.A., Kumar, P. et al. Raloxifene Inhibits NF-kB Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxictiy. Pathol. Oncol. Res. 22, 145–153 (2016). https://doi.org/10.1007/s12253-015-9988-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-015-9988-6

Keywords

Search

Navigation